TY - JOUR
T1 - Standardization, regulation, quality assurance and emerging technologies in hemostasis
T2 - issues, controversies, benefits, and limitations
AU - Favaloro, Emmanuel J
PY - 2007/4
Y1 - 2007/4
N2 - There are many benefits to the overall process of standardization for tests of hemostasis and thrombosis. Nevertheless, it should also be recognized there are several specific problems and limitations to this process, as highlighted in this review. Some of the issues are formidable, but it is hoped that they are not insurmountable. Sometimes, clinical pressures drive diagnostic test processes before they are formally proven to be of clinical value. Such clinical pressures drive diagnostic changes in the hemostasis laboratory, including the incorporation of new and emerging technologies, which in turn drives the need for evolving and effective external quality assurance. Incorporated into the diagnostic or test-performance process are a large number of organizations involved in driving standardization, with the ultimate intention of improving diagnostics, but this process will also have unintended potential for adverse outcomes. Although this review notes many of the benefits to the process, it focuses primarily on those negative factors that are often less obvious but still require attention and process review.
AB - There are many benefits to the overall process of standardization for tests of hemostasis and thrombosis. Nevertheless, it should also be recognized there are several specific problems and limitations to this process, as highlighted in this review. Some of the issues are formidable, but it is hoped that they are not insurmountable. Sometimes, clinical pressures drive diagnostic test processes before they are formally proven to be of clinical value. Such clinical pressures drive diagnostic changes in the hemostasis laboratory, including the incorporation of new and emerging technologies, which in turn drives the need for evolving and effective external quality assurance. Incorporated into the diagnostic or test-performance process are a large number of organizations involved in driving standardization, with the ultimate intention of improving diagnostics, but this process will also have unintended potential for adverse outcomes. Although this review notes many of the benefits to the process, it focuses primarily on those negative factors that are often less obvious but still require attention and process review.
KW - Antibodies, Antiphospholipid/biosynthesis
KW - Blood Coagulation Tests/methods
KW - Chemistry, Clinical/methods
KW - Clinical Laboratory Techniques/standards
KW - Fibrin Fibrinogen Degradation Products/biosynthesis
KW - Hemostasis
KW - Humans
KW - Lupus Coagulation Inhibitor/biosynthesis
KW - Quality Control
KW - Thrombophilia/diagnosis
KW - Thrombosis/diagnosis
KW - von Willebrand Factor/biosynthesis
U2 - 10.1055/s-2007-971816
DO - 10.1055/s-2007-971816
M3 - Review article
C2 - 17427064
SN - 0094-6176
VL - 33
SP - 290
EP - 297
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
IS - 3
ER -